iRECIST: how to do it

BACKGROUND: iRECIST for the objective monitoring of immunotherapies was published by the official RECIST working group in 2017. MAIN BODY: Immune-checkpoint inhibitors represent one of the most important therapy advancements in modern oncology. They are currently used for treatment of multiple malig...

Descripción completa

Detalles Bibliográficos
Autores principales: Persigehl, Thorsten, Lennartz, Simon, Schwartz, Lawrence H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6942293/
https://www.ncbi.nlm.nih.gov/pubmed/31900236
http://dx.doi.org/10.1186/s40644-019-0281-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6942293/
https://www.ncbi.nlm.nih.gov/pubmed/31900236
http://dx.doi.org/10.1186/s40644-019-0281-x

Ejemplares similares